PMID- 36578522
OWN - NLM
STAT- MEDLINE
DCOM- 20221230
LR  - 20230103
IS  - 1942-0994 (Electronic)
IS  - 1942-0900 (Print)
IS  - 1942-0994 (Linking)
VI  - 2022
DP  - 2022
TI  - Honokiol Ameliorates DSS-Induced Mouse Colitis by Inhibiting Inflammation and 
      Oxidative Stress and Improving the Intestinal Barrier.
PG  - 1755608
LID - 10.1155/2022/1755608 [doi]
LID - 1755608
AB  - Ulcerative colitis (UC) is a multifactor intestinal disease with increased 
      morbidity. Recently, pleiotropic drugs with exact biosafety have been urgently 
      needed. Honokiol (HKL) is the major bioactive component of traditional Chinese 
      medicine "Houpu," with almost no toxic effects and approved anti-inflammation, 
      antioxidant, antispasmodic, etc. effects. This study examined the therapeutic 
      effect of HKL in dextran sulfate sodium- (DSS-) induced experimental colitis. In 
      vivo, C57BL/6 mice received 3% DSS for seven days to generate UC, and HKL was 
      pretreated for five days and given during the whole DSS-induced period. In vitro, 
      RAW264.7 macrophages were stimulated with lipopolysaccharide (LPS) to induce 
      inflammation, and mouse colon epithelial cells (MCEC) were treated with HKL or 
      pretreated with HKL and then stimulated with LPS-induced macrophage supernate to 
      investigate the barrier enhancement roles. HKL significantly ameliorated disease 
      activity index (DAI), colon length, and histopathological scores in DSS-induced 
      colitis. The inflammatory mediators of interleukin 1beta (IL-1beta), interleukin 6 
      (IL-6), tumor necrosis factor alpha (TNF-alpha), inducible nitric oxide synthase (iNOS), 
      and cyclooxygenase-2 (COX2) were decreased, and the tight conjunction proteins 
      were increased in the HKL-treated group both in vivo and in vitro. Above all, HKL 
      can relieve experimental UC through anti-inflammation, antioxidant, and 
      epithelial barrier enhancement roles. These effects were associated with 
      peroxisome proliferator-activated receptor gamma (PPARgamma)/nuclear factor-kappaB (NF-kappaB) 
      p65, sirtuin3 (SIRT3)/adenosine 5'-monophosphate- (AMP-) activated protein kinase 
      (AMPK), and nuclear factor erythroid 2-related factor 2 (NRF2)/heme oxygenase 1 
      (HO1) signaling pathways. In conclusion, after further clinical studies, HKL may 
      be a promising drug for UC.
CI  - Copyright (c) 2022 Lu Wang and Junping Wang.
FAU - Wang, Lu
AU  - Wang L
AUID- ORCID: 0000-0003-4945-5332
AD  - Department of Gastroenterology, Second Hospital of Shanxi Medical University, 
      Taiyuan, China.
AD  - The Fifth Clinical Medical College of Shanxi Medical University, Taiyuan, Shanxi, 
      China.
FAU - Wang, Junping
AU  - Wang J
AUID- ORCID: 0000-0002-9360-4131
AD  - The Fifth Clinical Medical College of Shanxi Medical University, Taiyuan, Shanxi, 
      China.
AD  - Department of Gastroenterology, Fifth Hospital of Shanxi Medical University, 
      Taiyuan, Shanxi, China.
LA  - eng
PT  - Journal Article
DEP - 20221219
PL  - United States
TA  - Oxid Med Cell Longev
JT  - Oxidative medicine and cellular longevity
JID - 101479826
RN  - 11513CCO0N (honokiol)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Antioxidants)
RN  - 0 (NF-kappa B)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Interleukin-6)
RN  - 9042-14-2 (Dextran Sulfate)
SB  - IM
MH  - Animals
MH  - Mice
MH  - Lipopolysaccharides/adverse effects
MH  - Antioxidants/metabolism
MH  - Mice, Inbred C57BL
MH  - *Colitis/chemically induced/drug therapy/pathology
MH  - Inflammation/pathology
MH  - *Colitis, Ulcerative/chemically induced
MH  - Colon
MH  - NF-kappa B/metabolism
MH  - Anti-Inflammatory Agents/adverse effects
MH  - Interleukin-6/metabolism
MH  - Oxidative Stress
MH  - Dextran Sulfate/toxicity
MH  - Disease Models, Animal
PMC - PMC9792244
COIS- The authors have declared that no conflict of interest exists.
EDAT- 2022/12/30 06:00
MHDA- 2022/12/31 06:00
PMCR- 2022/12/19
CRDT- 2022/12/29 02:25
PHST- 2022/08/12 00:00 [received]
PHST- 2022/11/18 00:00 [revised]
PHST- 2022/11/25 00:00 [accepted]
PHST- 2022/12/29 02:25 [entrez]
PHST- 2022/12/30 06:00 [pubmed]
PHST- 2022/12/31 06:00 [medline]
PHST- 2022/12/19 00:00 [pmc-release]
AID - 10.1155/2022/1755608 [doi]
PST - epublish
SO  - Oxid Med Cell Longev. 2022 Dec 19;2022:1755608. doi: 10.1155/2022/1755608. 
      eCollection 2022.